Effect of glucagon-like peptide-1 on the beta cell response to glucose-dependent insulinotropic polypeptide in elderly patients with diabetes mellitus.
Meneilly
Graydon S
GS
Elahi
Dariush
D
D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005500:Follow-Up Studies; D005749:Gastric Inhibitory Polypeptide / Q000627:therapeutic use*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage*; D006801:Humans; D007262:Infusions, Intravenous; D007328:Insulin / Q000097:blood; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000378:metabolism; D016896:Treatment Outcome
D001786:Blood Glucose; D005765:Gastrointestinal Agents; D007328:Insulin; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1